INR:8459. players only sign Overview of new drugs approved worldwide in December 2019 SCLC is about to usher in more new therapies after immunotherapy breaks th ...

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced that it has entered into exclusive license ...

A woman has shared a video warning others about the common symptoms she experienced before being diagnosed with stage four lung cancer. Linda Chavez was 34 when she was diagnosed with a type of lung ...

Researchers conducted a retrospective study to examine the prognostic roles of Neutrophil-to-Lymphocyte Ratio (NLR) and ...

Secondary prevention for lung cancer involves screening methods that aim to detect the disease in its early stages, before ...

A panelist discusses how enhanced screening protocols combined with predictive analytics can accelerate Lambert-Eaton myasthenic syndrome (LEMS) detection in high-risk populations like patients with ...

The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227 gets EMA PRIME designation in relapsed extensive-stage small-cell lung cancer: London Saturday, December 21, 2024, 17:30 ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

(MENAFN- Investor Brand Network) NetworkNewsWire Editorial Coverage : More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment.

Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced a collaboration and license agreement with Shanghai Henlius ...

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...